We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ophthotech Corp. | NASDAQ:OPHT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.39 | 1.39 | 1.42 | 0 | 01:00:00 |
Delaware
|
|
20-8185347
|
(State or Other Jurisdiction of Incorporation
or Organization)
|
|
(I.R.S. Employer
Identification No.) |
One Penn Plaza, 35
th
Floor
New York, New York |
|
10119
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Large accelerated filer
o
|
|
Accelerated filer
x
|
Non-accelerated filer
o
|
|
Smaller reporting company
x
|
|
|
Emerging growth company
o
|
Title of
Securities to be Registered |
|
Amount to be
Registered (1) |
|
Proposed
Maximum Offering Price Per Share |
|
Proposed
Maximum Aggregate Offering Price |
|
Amount of
Registration Fee |
|
Common Stock, $0.001 par value per share
|
|
1,655,887 shares (2)
|
|
$ 1.33 (3)
|
|
$ 2,202,330 (3)
|
|
$ 267
|
|
(1)
|
In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
|
(3)
|
Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and 457(h) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of $1.33, the average of the high and low sale prices of the Registrant’s Common Stock as reported on The Nasdaq Global Select Market on February 21, 2019, in accordance with Rule 457(c) under the Securities Act of 1933, as amended.
|
Number
|
Description
|
***
|
Previously filed with the Securities and Exchange Commission as an Exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 and incorporated herein by reference.
|
|
OPHTHOTECH CORPORATION
|
|
|
By:
|
/s/ Glenn P. Sblendorio
|
|
|
Glenn P. Sblendorio
|
|
|
President and Chief Executive Officer
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Glenn P. Sblendorio
|
|
President, Chief Executive Officer and Director (principal executive officer)
|
|
February 28, 2019
|
Glenn P. Sblendorio
|
|
|
|
|
|
|
|
|
|
/s/ David F. Carroll
|
|
Senior Vice President, Chief Financial Officer and Treasurer (principal financial and accounting officer)
|
|
February 28, 2019
|
David F. Carroll
|
|
|
|
|
|
|
|
|
|
/s/ David R. Guyer
|
|
Executive Chairman of the Board of Directors
|
|
February 28, 2019
|
David R. Guyer, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Axel Bolte
|
|
Director
|
|
February 28, 2019
|
Axel Bolte
|
|
|
|
|
|
|
|
|
|
/s/ Thomas Dyrberg
|
|
Director
|
|
February 28, 2019
|
Thomas Dyrberg, M.D., D.M.Sc.
|
|
|
|
|
|
|
|
|
|
/s/ Jane P. Henderson
|
|
Director
|
|
February 28, 2019
|
Jane P. Henderson
|
|
|
|
|
|
|
|
|
|
/s/ David E. Redlick
|
|
Director
|
|
February 28, 2019
|
David E. Redlick
|
|
|
|
|
|
|
|
|
|
/s/ Adrienne L. Graves
|
|
Director
|
|
February 28, 2019
|
Adrienne L. Graves, Ph.D.
|
|
|
|
|
|
|
|
|
|
/s/ Jane P. Henderson
|
|
Director
|
|
February 28, 2019
|
Jane P. Henderson
|
|
|
|
|
|
|
|
|
|
/s/ David E. Redlick
|
|
Director
|
|
February 28, 2019
|
David E. Redlick
|
|
|
|
|
|
|
|
|
|
/s/ Calvin W. Roberts
|
|
Director
|
|
February 28, 2019
|
Calvin W. Roberts, M.D.
|
|
|
|
|
1 Year OPHTHOTECH CORP. Chart |
1 Month OPHTHOTECH CORP. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions